Examine the potential and challenges of population-scale genome sequencing for public health in a genetically diverse country like India.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →In this answer
Population-scale genome sequencing maps the genetic variation of an entire population. India has begun this through GenomeIndia, a Department of Biotechnology (DBT) project that has sequenced 10,000 genomes [2]. The DBT records whole-genome sequencing of 10,074 individuals [3]. The potential is large, but it pays off only if the data reaches the clinic.
Potential
- India-specific reference data: Because of India's genetic diversity, risk estimates from foreign populations may not fit Indian patients. GenomeIndia covers 84 populations and more than 400 genetic traits [1].
- Precision medicine: The DBT calls the dataset a foundation for treatment tailored to a person's genes, lifestyle and environment [3].
- Risk stratification: Biomarkers identify high-risk groups. For example, women with gestational diabetes who may later develop Type 2 diabetes can be screened first [1].
- Rare diseases: These are mostly genetic, so genomics helps diagnosis. The National Policy for Rare Diseases (NPRD), 2021 supports indigenous research through a National Consortium [4].
- Indigenous capability: CMC Vellore's haemophilia gene therapy, published in the New England Journal of Medicine, shows that Indian research can compete globally [1].
Challenges
- Mismatch with the disease burden: Metabolic disease is rising among the young mainly because of changing diets and less physical activity [1]. Sequencing cannot replace food policy and screening.
- Delivery gap: NP-NCD screens only people aged 30 and above [5]. Young people that research flags as high-risk get no routine follow-up.
- Privacy and consent: Genomic data is highly sensitive. The DPDP Act, 2023 governs digital personal data [6], but national biobanks still need specific rules on consent and benefit-sharing.
- Cost and equity: Rare-disease treatment is costly and few medicines exist [1]. The benefits may reach better-off patients first.
- Fragmented administration: DBT runs genomics [2] and the Health Ministry (MoHFW) runs NPRD [4]. Without coordination, research findings may not reach the health system.
Genome sequencing gives India data that no other country will produce for it, but it is only useful if it reaches patients. The way forward is to:
- send genomic and biomarker risk flags to NP-NCD clinics;
- screen identified high-risk groups before age 30;
- write genomics-specific consent rules under the DPDP framework;
- use the NPRD Consortium to scale up low-cost indigenous therapies.
If genomics guides public health rather than replacing it, it can advance the right to health under Article 21, SDG 3 and Viksit Bharat 2047 [1].
Sources
- 1PIB press release: Dr Jitendra Singh at THE WEEK Health Summit 2026GenomeIndia's 84 populations and 400+ traits; gestational-diabetes biomarkers; lifestyle-driven disease among the young; CMC Vellore gene therapy in NEJM; rare-disease cost burden; Viksit Bharat 2047
- 2PIB, Ministry of Science & Technology: GenomeIndia sequences 10,000 genomes (27 Feb 2024)10,000 genomes; DBT/MoS&T ownership
- 3DBT GenomeIndia Digest (27-02-2024)whole-genome sequencing of 10,074 individuals; foundation for precision medicine
- 4PIB, MoHFW: National Policy for Rare Diseases, 2021National Consortium for indigenous research; MoHFW ownership
- 5MoHFW: NP-NCD Operational Guidelinesscreening of persons aged 30 and above
- 6Digital Personal Data Protection Act, 2023 (India Code)legal framework for digital personal data